Haemonetics Corp (NYSE: HAE) has reported earnings for its third fiscal quarter (ending December 31) of $0.75 versus $0.62 for the same period a year ago — an increase of 21%. For the latest four quarters through December 31, E.P.S. were $2.56 versus $2.50 for the same period a year ago — an increase of 2%.
Recent Price Action
Haemonetics Corp (NYSE: HAE) stock suffered a major decline of -11.6% on 2/6/25. The shares closed at $62.99. Moreover, exceptionally high trading volume at 505% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months and has declined -7.8% during the last week.
Current PriceTarget Research Rating
Haemonetics has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Haemonetics has a neutral Appreciation Score of 43 and a neutral Power Rating of 42, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment